News from nordic nanovector A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 11, 2019, 08:55 ET Nordic Nanovector Completes Patient Enrolment Into Phase 1 Trial of Betalutin® in Diffuse Large B-cell Lymphoma (DLBCL)

Nordic Nanovector ASA (OSE: NANO) announces that the final patient has been enrolled in the LYMRIT 37-05 clinical trial of Betalutin®...


Jun 17, 2019, 06:41 ET Nordic Nanovector ASA: Share Capital Increase Registered

Reference is made to the stock exchange notice published by Nordic Nanovector ASA (the "Company") (OSE: NANO) on 31 May 2019 where the Company...


Jun 11, 2019, 02:13 ET Nordic Nanovector Presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting

Nordic Nanovector ASA (OSE: NANO) announces that the company and its collaborators will present data and analyses from its preclinical studies with...


Jun 06, 2019, 01:14 ET Nordic Nanovector to Present Preclinical Studies With 212Pb-NNV003, a Novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019

Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with...


Jun 03, 2019, 01:13 ET Nordic Nanovector: European Patent Granted for Betalutin® or Humalutin® in Combination With Anti-CD20 Antibodies for Treating NHL

Nordic Nanovector ASA (OSE: NANO) announces that the European Patent Organisation (EPO) has granted the company's European Patent covering the use of ...


May 31, 2019, 04:10 ET Nordic Nanovector ASA: Increase of Share Capital

Three of the board members of Nordic Nanovector ASA (the "Company"), Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a ...


May 27, 2019, 02:13 ET Nordic Nanovector to Present at Redeye Pre-ASCO Seminar, Jefferies Healthcare Conference and ABGSC Oncology Seminar

Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming...


May 23, 2019, 08:40 ET Nordic Nanovector ASA - Allocation of PSUs

The Board of Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the "Company") has on 23 May 2019 resolved to grant 10,000 Performance Share...


May 23, 2019, 01:29 ET Nordic Nanovector ASA - Results for the First Quarter 2019

Nordic Nanovector ASA (OSE: NANO) announces its results for the first quarter 2019. A presentation by the company's senior management team will take...


May 21, 2019, 06:01 ET Nordic Nanovector: Archer-1 Phase 1b Betalutin®/Rituximab Combination Trial Advances to Next Cohort

Nordic Nanovector ASA (OSE: NANO) announces that following a safety review of the first patients in the ongoing Archer-1 (LYMRIT 37-07) trial...


May 16, 2019, 02:12 ET Nordic Nanovector ASA: Invitation to First Quarter 2019 Results Presentation and Webcast

Nordic Nanovector ASA (OSE: NANO) announces that it will report its first quarter 2019 results on Thursday, 23 May 2019. A presentation by Nordic...


May 10, 2019, 04:33 ET Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors

Reference is made to the minutes from Nordic Nanovector ASA's (the "Company") (OSE: NANO) annual general meeting held on 25 April 2019 in Oslo,...


Apr 29, 2019, 02:15 ET Nordic Nanovector Appoints Fredrik Haavind as Head of Legal and Compliance

Nordic Nanovector ASA (OSE: NANO) announces the appointment of Fredrik Haavind as the newly established Head of Legal and Compliance. Mr Haavind has...


Apr 25, 2019, 10:29 ET Nordic Nanovector ASA: Annual General Meeting Held

The Annual General Meeting of Nordic Nanovector ASA (the "Company") (OSE: NANO) was held today on 25 April 2019 in Oslo, Norway. All proposals were...


Apr 10, 2019, 01:22 ET Nordic Nanovector: Safety Review Committee Approves Advancing to Final Dosing Regimen in Phase 1 Trial of Betalutin® in DLBCL

Nordic Nanovector ASA (OSE: NANO) announces that the Safety Review Committee (SRC) for the ongoing LYMRIT 37-05 clinical trial of...


Apr 04, 2019, 03:12 ET Nordic Nanovector ASA: Notice of Annual General Meeting on 25 April 2019

Notice is given that the Annual General Meeting of Nordic Nanovector ASA will be held on 25 April 2019 at 15.00 hours CEST at Thon Hotel Vika Atrium, ...


Apr 03, 2019, 14:17 ET Nordic Nanovector ASA Publishes 2018 Annual Report

Nordic Nanovector ASA has today published its 2018 Annual Report, including the complete 2018 Annual Accounts with notes. This report is attached to...


Apr 02, 2019, 01:10 ET Nordic Nanovector: Promising Results From Preclinical Studies With a Novel CD37-targeted Alpha Therapy for B-cell Tumours Presented at TAT11

Nordic Nanovector ASA (OSE: NANO) notes that promising results from its preclinical research collaboration to develop a novel CD37-targeting alpha...


Mar 28, 2019, 04:00 ET Nordic Nanovector to Present at DNB's SME Conference and Kempen Life Science Conference

Nordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming...


Mar 18, 2019, 07:13 ET Nordic Nanovector ASA: Increased Share Capital Following Exercise of Employee Share Options

An individual participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous share option program, not being a primary insider, has...


Mar 14, 2019, 06:42 ET Nordic Nanovector ASA - Share Capital Increase Registered

Reference is made to the stock exchange notice on 6 March 2019 where Nordic Nanovector ASA (the "Company") announced the final result of the repair...


Mar 12, 2019, 06:15 ET Financial Calendar for Nordic Nanovector ASA

FINANCIAL YEAR 2018 03.04.2019 - Annual Report FINANCIAL YEAR 2019 22.08.2019 - Half-yearly Report 25.04.2019 - Annual General Meeting 23.05.2019 -...


Mar 11, 2019, 04:21 ET Nordic Nanovector to Attend Cowen Health Care Conference, BioCapital Europe and Stifel Nordic Healthcare Seminar

ordic Nanovector ASA (OSE: NANO) announces that members of its senior management team will participate and present at the following upcoming investor ...


Mar 06, 2019, 12:04 ET Nordic Nanovector ASA - Final Result of the Repair Offering

Reference is made to the stock exchange notice on 20 February 2019 where Nordic Nanovector ASA (the "Company") announced the commencement of a repair ...


Mar 04, 2019, 07:40 ET Nordic Nanovector ASA: Increase of Share Capital

The former chairman of Nordic Nanovector ASA (the "Company"), Ludvik Sandnes, has resolved to exercise a total number of 27,121 RSUs that were issued ...